Press Room

RDD 2016

Start
Sunday, April 17, 2016 - 00:00
End
Thursday, April 21, 2016 - 23:45
Location: Arizona, USA
Booth Number: 14

The Respiratory Drug Delivery (RDD®) 2016 will be held at the Westin Kierland Resort, Phoenix, Arizona, April 17-21, 2016.

Hovione will be present with a table and a set of posters.

 

HOVIONE'S POSTERS

Particle Engineered Glycopyrrolate Inhalation Grade: A Comprehensive Solid State Characterization Study
Susana Campos

From TwinCaps® to TwinMax™: Optimizing a Disposable Inhaler for High Dosage Applications Through CFD
João Fernandes

Impact of the API Concentration on the Solid State Properties and Aerodynamic Performance of Composite Particles for DPIs
Diana Fernandes

Strategies to Deliver Doxycycline Monohydrate via Inhalation
Maria Palha

Alternatives to Lactose-only Carrier-based Formulations: The Use of Mannitol and Magnesium Stearate
Bruno Santos

Using Laser Diffraction for the Advanced Characterization of Nebulization Products - Part 1: Discriminative Power via Standard Data Analysis
Isabel Sequeira Lopes

Using Laser Diffraction for the Advanced Characterization of Nebulization Products - Part 2: Extended Data Analysis and Correlation with Cascade Impaction
Isabel Sequeira Lopes

Dry Powder Inhalers Characterization: Comparison Between Full and Abbreviated Impactor Testing
Sofia Silva

 

Details about the event
To find more about the posters, contact us

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025